Appointment of Chief Financial Officer

Frontier IP Group plc

05 May 2026

 

RNS: 9058C

AIM: FIPP

5 May 2026

Frontier IP Group plc

("Frontier IP" or the "Group")

Appointment of Chief Financial Officer

Frontier IP, a specialist in commercialising intellectual property, is pleased to announce the appointment of Shaun Claydon as Chief Financial Officer and Company Secretary with immediate effect.

Shaun is an ICAEW-qualified chartered accountant with extensive experience in corporate finance, scaling businesses, and delivering successful exits. He brings more than 20 years' experience in senior financial leadership roles, including more than 15 years at board-level, with a focus on fundraising, mergers and acquisitions ("M&A"), and growth strategy.

Shaun has held board-level positions in a number of private and public companies, most recently as Chief Financial Officer at Actimed Therapeutics, where he co-led a Series B equity funding round securing a multi-million investment for clinical programmes. Prior to this Shaun served as Chief Financial Officer of Destiny Pharma for six years between 2018 and 2024. Before transitioning to executive roles, Shaun gained extensive experience in financial consultancy and senior corporate finance roles including at HSBC Investment Banking, BDO LLP, Evolution Securities plc and PwC.

He is currently a non-executive director of spirits group Distil plc.

Further to the announcement made by the Company on 6 November 2025, Jo Stent, previous Chief Financial Officer of the Group, has now stepped down from the Group's Board. However, Jo will remain employed with the Group for an additional short period of time to ensure an orderly handover of responsibilities to Shaun and to provide additional support on both a corporate level and with certain portfolio companies.

Neil Crabb, Chief Executive of Frontier IP, said: "I am delighted to welcome Shaun to our Board of Directors and to the wider Group. Shaun brings significant expertise and experience, particularly in areas of key focus for our portfolio companies, including equity fundraising, IPOs and M&A. He will play a vital role in the next stage of our growth as we focus on developing our portfolio companies towards exit."

Shaun Claydon, Chief Financial Officer, said: "I am very pleased to be joining Frontier IP at this important stage of its development. I look forward to helping the Group and its portfolio companies realise their full potential. I look forward to working with Jo over the coming weeks to ensure a seamless handover of responsibilities."

Further regulatory disclosures

The following additional information is provided in accordance with Rule 17 and Schedule Two Paragraph (g) of the AIM Rules for Companies.

Shaun Claydon, aged 57, is, or has been, a director or partner of the following companies or partnerships during the previous five years:

Current directorships and/or partnerships	Former directorships and/or partnerships within the last five years
Distil plc	Destiny Pharma Limited Destiny Pharma (Brighton) Limited Destiny Pharma EU Limited (Ireland)

Shaun Claydon was previously a director of Destiny Pharma Limited ("Destiny") (formerly known as Destiny Pharma plc) until 30 September 2024. Destiny appointed an administrator on 21 August 2024 and was placed into creditors' voluntary liquidation on 1 August 2025.

ENQUIRIES

Frontier IP Group Plc Neil Crabb, Chief Executive Andrew Johnson, Communications & Investor Relations Company website: www.frontierip.co.uk	[e-mail] M: 07415 888 425 [e-mail]
Allenby Capital Limited (Nominated Adviser) Nick Athanas	T: 0203 328 5656
Singer Capital Markets (Broker) James Fischer	T: 0207 496 3000

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

END